Companies · Other Health Care

iRhythm Technologies, Inc.

San Francisco · Other Health Care

Diligence memoA one-page analyst read on iRhythm Technologies, Inc. — recommendation, valuation, rhythm, risks.
$118.6M
Total raised · real
9
Rounds
1.6×
Latest step-up
Top 4%
Sector rank · raised
Series B
Latest stage · inferred · Fri May 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

iRhythm Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.37× the median modeled value of Series B Other Health Care companies in 2013–2015 (85 peers) — value vs value, same stage and era.
  • Within the normal band (137% of peer median) for its niche.
Dormant
  • Last raise 12.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

iRhythm Technologies, Inc. is one of 5377 Other Health Care companies tracked from San Francisco. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2009-04-10 Raised $6.5M (real) Modeled valuation $132M (est)Series A2009Series A · 2010-05-12 Raised $10M (real) Modeled valuation $202M (est)Series A2010Series B · 2011-04-26 Raised $22M (real) Modeled valuation $491M (est)Series B2011Series A · 2011-04-26 Raised $10.0M (real) Modeled valuation $201M (est)Series A2011Series A · 2011-04-26 Raised $6.7M (real) Modeled valuation $135M (est)Series A2011Series B · 2012-11-01 Raised $3.5M (real) Modeled valuation $78M (est)Series B2012Series B · 2013-03-27 Raised $15M (real) Modeled valuation $335M (est)Series B2013Series B · 2014-05-16 Raised $17M (real) Modeled valuation $384M (est)Series B2014Series B · 2014-05-16 Raised $27M (real) Modeled valuation $606M (est)Series B2014+$10M+$22M+$10.0M+$6.7M+$3.5M+$15M+$17M+$27MCumulative $119M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.5M · 2009
Series A extension$10.0M · 2010
Series B$22.1M · 2011
Bridge · Series B-stage$10.0M · 2011smaller follow-on
Bridge · Series B-stage$6.7M · 2011smaller follow-on
Series B extension$3.5M · 2012
Series B extension$15.1M · 2013
Series B extension$17.3M · 2014
Series B extension$27.3M · 2014

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$605.8M
Base estimate est.
$64.3M
Conservative case
$2.3B
Upside case
$151.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $131.9M · 2009-04-102009Series A · modeled $201.8M · 2010-05-12Series B · modeled $490.7M · 2011-04-26Series A · modeled $201.2M · 2011-04-26Series A · modeled $134.6M · 2011-04-26Series B · modeled $77.5M · 2012-11-01Series B · modeled $334.7M · 2013-03-27Series B · modeled $384.2M · 2014-05-16Series B · modeled $605.8M · 2014-05-162014
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
6.0 yr
Elapsed time used
12.1 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$23.3M/yr
Capital velocity
17.2 yr
On record since
2009
First round
9
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 49× above median
This company$118.6M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.5× above median
This company$27.3M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 27× above median
This company$605.8M
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #25 of 85.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Drynachan, Llc · Series B Raised $40.0M · modeled $886.2M (est)Vistria SHC Holdings, LLC · Series B Raised $39.7M · modeled $879.5M (est)Ebh Holding Company, Inc. · Series B Raised $70.9M · modeled $871.1M (est)Orthopediatrics Corp · Series B Raised $57.5M · modeled $864.0M (est)Assurerx Health, Inc · Series B Raised $51.5M · modeled $828.4M (est)IMRIS Inc. · Series B Raised $36.8M · modeled $816.0M (est)Remedy Partners, Inc. · Series B Raised $56.4M · modeled $795.3M (est)Hansen Medical Inc · Series B Raised $126.0M · modeled $775.4M (est)BCOM Investment Partners, LLC · Series B Raised $34.5M · modeled $764.3M (est)Michigan Critical Care Consultants, Inc. · Series B Raised $34.0M · modeled $753.2M (est)HY Holdings, Inc. · Series B Raised $33.0M · modeled $731.1M (est)Medical Solutions L.L.C. · Series B Raised $32.5M · modeled $720.0M (est)iRhythm Technologies, Inc. (this company) Raised $118.6M · modeled $605.8M (est)iRhythm Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Drynachan, LlcSeries B$40.0M$886.2M2.00×
Vistria SHC Holdings, LLCSeries B$39.7M$879.5M1.99×
Ebh Holding Company, Inc.Series B$70.9M$871.1M1.97×
Orthopediatrics CorpSeries B$57.5M$864.0M1.95×
Assurerx Health, IncSeries B$51.5M$828.4M1.87×
IMRIS Inc.Series B$36.8M$816.0M1.84×
Remedy Partners, Inc.Series B$56.4M$795.3M1.79×
Hansen Medical IncSeries B$126.0M$775.4M1.75×
BCOM Investment Partners, LLCSeries B$34.5M$764.3M1.72×
Michigan Critical Care Consultants, Inc.Series B$34.0M$753.2M1.70×
HY Holdings, Inc.Series B$33.0M$731.1M1.65×
Medical Solutions L.L.C.Series B$32.5M$720.0M1.62×
iRhythm Technologies, Inc. this companySeries B$118.6M$605.8M1.37×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.5M2009-04-10$29.7M$131.9M90%
Series A$10.0M2010-05-12$45.5M$201.8M90%
Series B$22.1M2011-04-26$123.1M$490.7M90%
Series A$10.0M2011-04-26$45.3M$201.2M90%
Series A$6.7M2011-04-26$30.3M$134.6M90%
Series B$3.5M2012-11-01$19.4M$77.5M90%
Series B$15.1M2013-03-27$83.9M$334.7M90%
Series B$17.3M2014-05-16$96.4M$384.2M90%
Series B$27.3M2014-05-16$151.9M$605.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.5M2009-04-10
    • First recorded raise — entered as Series A.
  2. Series A$10.0M2010-05-12
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
  3. Series B$22.1M2011-04-26
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
  4. Series A$10.0M2011-04-26
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× smaller than the prior — bridge or down round.
  5. Series A$6.7M2011-04-26
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
  6. Series B$3.5M2012-11-01
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
  7. Series B$15.1M2013-03-27
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 4.3× larger than the prior — scaling up.
  8. Series B$17.3M2014-05-16
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  9. Series B$27.3M2014-05-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× larger than the prior — scaling up.
Intelligence
2015 ~Q1
Modeled next raise · ~8mo cadence
$43.1M
Modeled next size est.range $28.0M$69.0M
1.6×
Last step-up
$23.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Goldberg10 other2009-04
William N. Starling4 other2010-05
William Starling3 other2009-04
Michael D. Goldberg2 other2010-05
Shelly D. Guyer2 other2010-05
Uday N. Kumar2 other2010-05
William Willis2 other2009-04
Casper E. De Clercq1 other2014-05
Joshua L. Green1 other2011-04
Uday Kumar1 other2009-04
William F. Willis1 other2010-05
Casper L. De Clercq2013-03
Chris E. Grant2014-05
Hardwin Mead2009-04
Judith K. Lenane2011-04
Judith N. Lenane2011-04
Kevin M. King2012-11
Matthew M. Garrett2013-03
Raymond K. Scott2014-05
R. Hardwin Mead2012-11
R. Hardwin R. Mead2010-05
Roberta Katz2009-04
Roberta R. Katz2010-05
Sam E. Brasch2011-04
Registry & provenance

iRhythm Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1388658
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Yor Labs, Inc.BiotechnologySeries B$37.7M$167.2Mnetwork5 shared operators · same stage
Element Science, Inc.Other Health CareSeries C$97.6M$1.2Bnetwork1 shared operator · same sector
Neuronetics, Inc.Other Health CareSeries B$118.7M$332.3Msame sector · same stage
Headspace, Inc.Other Health CareSeries B$115.9M$860.6Msame sector · same stage
Transcend Medical IncOther Health CareSeries B$122.3M$648.4Msame sector · same stage
Hansen Medical IncOther Health CareSeries B$126.0M$775.4Msame sector · same stage
Optiscan Biomedical CorpOther Health CareSeries B$131.6M$443.1Msame sector · same stage
Invuity, Inc.Other Health CareSeries B$105.7M$507.3Msame sector · same stage
Frequently asked
How much funding has iRhythm Technologies, Inc. raised?
iRhythm Technologies, Inc. has raised approximately $118.6M in disclosed capital across 9 recorded financing rounds, aggregated from public filings.
What is iRhythm Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for iRhythm Technologies, Inc. is approximately $605.8M (modeled range $64.3M–$2.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is iRhythm Technologies, Inc. at?
iRhythm Technologies, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri May 16.
What does iRhythm Technologies, Inc. do and where is it based?
iRhythm Technologies, Inc. operates in the Other Health Care sector, based in San Francisco.
Explore related

See where iRhythm Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at iRhythm Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.